Patenting Landscape in India 2009 October 2009
Download 0.49 Mb.
|
- Navigate this page:
- Top Domestic Filers at the IPO
Top Filers at the IPOEvalueserve has identified the top patent filers at the IPO for the past four years by analysing 112,515 patent applications published by the IPO during the period January 2005 to December 2008 [6]. Table 1 lists the top 25 filers for the calendar years 2007 and 2008. The top patent filers have been selected on the basis of their published patent applications. Generally, most patent jurisdictions publish a patent application 18 months after its earliest effective filing date, after which it is considered to be in the public domain. Before this publication, the content and the very act of filing are considered proprietary information that is closely guarded by most filers. The top 25 filers list includes 11 corporations from the electronics and telecom domain, and 8 from the pharmaceuticals and chemicals domain. It is interesting to note that Qualcomm has emerged as the top filer for both 2007 and 2008. During the period 2005–08, Qualcomm had 2,068 published applications at the IPO, which constitutes about 63% of its filing with the USPTO and 45% of its PCT filings during the same period. This shows how seriously Qualcomm protects its innovations in India, which is the world’s fastest-growing mobile market, growing at the rate 18% annually [7]. In addition, General Motors, Wockhardt, General Electric, Tata Group, LG Electronics, Research in Motion, 3M, Alcatel-Lucent and Sony Ericsson have significantly improved their rankings. In contrast, the rankings of Philips, Bayer, Microsoft and AstraZeneca have dropped marginally.
The top 50 patent filers at the IPO for 2005 to 2008 have been listed in the Appendix (Table 2). Interestingly, only four Indian organisations— the Council of Scientific and Industrial Research (CSIR), Ranbaxy Laboratories, Dr. Reddy’s Laboratories and Tata Group—appear in the list of top 50 patent filers. Top Domestic Filers at the IPOThe top 200 patent filers’ list (for 2005–08) is dominated by foreign and multinational firms. Evalueserve found that only 20 of the top 200 filers, i.e., 10%, are ‘pure-bred’ Indian organisations. Table 3 in the Appendix lists these 10 Indian organisations. Among these 20 organisations, 10 are pharmaceutical companies, 5 are research institutes and 1 is a government-owned enterprise. These 20 organisations are CSIR, Ranbaxy Laboratories, Dr. Reddy's Laboratories, Tata Group, Indian Institute of Technology, Bharat Heavy Electricals, Cadila, Steel Authority of India, Orchid Chemicals, Larsen & Toubro, Cipla, DRDO, TVS Group, Sun Pharmaceutical Industries, Aurobindo Pharma, Indian Council of Agricultural Research, ISRO, Panacea Biotec, Torrent Pharmaceuticals and Matrix Laboratories. It is encouraging to note that most of these organisations have improved their patenting intensity over the last year which is reflected from their improved scores in the revenue to patent-count ratio (hereinafter referred to as patenting intensity ratio). Lower the ratio for a company, better is the investment made by the corporation in protecting its intellectual capital using patents.
Directory: wp-content -> uploads -> 2009 2009 -> Guide to learn how to install, set up and access the music you need today! 2009 -> Terry L. Root 2009 -> For immediate release 2009 -> A parent-Friendly Handbook Things you’ll be glad to know about 2009 -> Children and adolescents, trauma and disasters 2009 -> Children and adolescents, trauma and disasters. A reference list compiled by dr philos. Atle Dyregrov Center for Crisis Psychology, Bergen, Norway 2009 -> Children and adolescents, trauma and disasters. A reference list compiled by dr philos. Atle Dyregrov Center for Crisis Psychology, Bergen, Norway 2009 -> Children and adolescents, trauma and disasters 2009 -> Mobile Chipset Applications Processor Download 0.49 Mb. Share with your friends:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||